Figure 1. Combination therapy of MK-4482 and PF-07321332 reduces clinical scores in rhesus macaques.

Experimental design (A). Rhesus macaques (n = 5) were infected with 2 × 10⁶ TCID₅₀ SARS-CoV-2 by combined intranasal and intratracheal routes. Treatments were started 12 hours postinfection, with continued dosing every 12 hours. Clinical exams were conducted on 1, 2, and 4 dpi, and animals were euthanized and necropsied on 4 dpi. Clinical scoring (B). Animals were scored daily for clinical signs of disease over the course of the study. AUC analysis of clinical scoring (C). Clinical scores were calculated for each animal per day; AUC was then calculated over the course of the study and displayed in minimum-to-maximum box plot with median displayed. Ordinary 1-way ANOVA with Dunnett’s multiple comparisons test, single pooled variance, were used to evaluate significance (*P value = 0.01 to 0.05). Nonsignificant results are not indicated.